Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | CTSB | P07858 | 2/20 | 0.39 |
| ▸ | CTSH | P09668 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5523667 | 0.83 | CTSK (0.40) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL5523324 | 0.82 | CTSK (0.56) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL1733951 | 0.76 | SLC1A3 (0.44) | LTA4H | |
| SCHEMBL5525570 | 0.76 | PSEN1 (0.40) | CTSKCTSLCTSBCTSHLTA4H | |
| SCHEMBL5529805 | 0.74 | LTA4H (0.39) | CTSKCTSLCTSBCTSHCPB2 | |
| SCHEMBL1733993 | 0.74 | SLC1A3 (0.42) | CPB2LTA4H | |
| SCHEMBL5525962 | 0.74 | PSEN1 (0.47) | CTSKCTSLCTSBATM | |
| SCHEMBL5529256 | 0.71 | ATM (0.56) | CTSKCTSLCTSBCTSSATM | |
| SCHEMBL13423682 | 0.70 | LTA4H (0.40) | CTSKCTSLCTSBCTSHCTSS | |
| SCHEMBL8703007 | 0.70 | CTSK (0.41) | CTSKCTSLCTSBCTSHCPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | AXYS PHARMACEUTICALS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1399146-A4 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARM INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | AXYS PHARMACEUTICALS, INC. | 2004-07-29 | — | — | US | disclosed |
| EP-1399146-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2004-03-24 | — | — | EP | disclosed |
| WO-2002098406-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232654-A1 | Novel Compounds and Compositions as Cathepsin Inhibitors | CTSS, CTSB, CTSE | CTSK 8/4885CTSL 11/4885CTSB 2/4885 |
| US-20040147503-A1 | Antiarthritic agents; muscular dystrophy; antiinflammatory agents; antitumor agents; glomerulonephritis | CAPNS1, CTSS, CTSV | CTSK 14/4885CTSL 19/4885CTSB 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.